User profiles for Joost L. Boormans
 | JL BoormansUrologist, Erasmus MC, Rotterdam Verified email at erasmusmc.nl Cited by 5838 |
Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic …
JL Boormans, JM de Castro, L Marconi, Y Yuan… - European urology, 2018 - Elsevier
… Author links open overlay panel Joost L. Boormans a † , Javier Mayor de Castro b † , Lorenzo
Marconi c , Yuhong Yuan d , M. Pilar Laguna Pes e , Carsten Bokemeyer f , Nicola Nicolai …
Marconi c , Yuhong Yuan d , M. Pilar Laguna Pes e , Carsten Bokemeyer f , Nicola Nicolai …
Systematic review of immune checkpoint inhibition in urological cancers
M Rijnders, R de Wit, JL Boormans, MPJ Lolkema… - European Urology, 2017 - Elsevier
… Author links open overlay panel Maud Rijnders a , Ronald de Wit a , Joost L. Boormans b ,
… Critical revision of the manuscript for important intellectual content: Boormans, Lolkema, van …
… Critical revision of the manuscript for important intellectual content: Boormans, Lolkema, van …
Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy
Background An early report on the molecular subtyping of muscle-invasive bladder cancer (MIBC)
by gene expression suggested that response to neoadjuvant chemotherapy (NAC) …
by gene expression suggested that response to neoadjuvant chemotherapy (NAC) …
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm …
…, GS Kulkarni, EM Uchio, JL Boormans… - The Lancet …, 2021 - thelancet.com
Background Standard treatment for high-risk non-muscle-invasive bladder cancer is transurethral
resection of bladder tumour followed by intravesical BCG immunotherapy. However, …
resection of bladder tumour followed by intravesical BCG immunotherapy. However, …
Targeted therapies in bladder cancer: an overview of in vivo research
…, TCM Zuiverloon, AR Alberts, JL Boormans… - Nature reviews …, 2015 - nature.com
Survival of patients with muscle-invasive bladder cancer is poor and new therapies are
needed. Currently, none of the targeted agents that are approved for cancer therapy have been …
needed. Currently, none of the targeted agents that are approved for cancer therapy have been …
Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder …
Background The PURE-01 study (NCT02736266) evaluated the use of pembrolizumab before
radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). Objective To evaluate …
radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). Objective To evaluate …
EAU-ESMO Consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort†: under the …
…, A Birtle, PC Black, BH Bochner, M Bolla, JL Boormans… - European urology, 2020 - Elsevier
Background Although guidelines exist for advanced and variant bladder cancer
management, evidence is limited/conflicting in some areas and the optimal approach remains …
management, evidence is limited/conflicting in some areas and the optimal approach remains …
Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy
…, KA van der Keur, JL Boormans, L Dyrskjøt… - The Journal of …, 2017 - auajournals.org
Purpose : Only 3% to 28% of patients referred to the urology clinic for hematuria are diagnosed
with bladder cancer. Cystoscopy leads to high diagnostic costs and a high patient burden…
with bladder cancer. Cystoscopy leads to high diagnostic costs and a high patient burden…
[HTML][HTML] Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice
GJ Van Leenders, JL Boormans, CJ Vissers… - Modern …, 2011 - nature.com
Genomic rearrangements involving genes encoding erythroblast transformation-specific
transcription factors are commonly present in prostate cancer. The TMPRSS2–ERG gene fusion …
transcription factors are commonly present in prostate cancer. The TMPRSS2–ERG gene fusion …
Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
…, GN Thalmann, E Davicioni, JL Boormans… - Clinical cancer …, 2019 - AACR
Purpose: After cisplatin-based neoadjuvant chemotherapy (NAC), 60% of patients with
muscle-invasive bladder cancer (MIBC) still have residual invasive disease at radical cystectomy. …
muscle-invasive bladder cancer (MIBC) still have residual invasive disease at radical cystectomy. …